Agents Used to Treat Musculoskeletal Health Alterations.

Slides:



Advertisements
Similar presentations
Neurological Diseases Jerry Carley RN, MSN, MA, CNE
Advertisements

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 16 Drugs That Block Nicotinic Cholinergic Transmission: Neuromuscular Blocking.
INDIRECT CHOLINOMIMETICS Pharmacology Department
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 15 Cholinesterase Inhibitors and Their Use in Myasthenia Gravis.
Myasthenia Gravis Dr. Belal M. Hijji, RN. PhD February 29, 2012.
Muscle weakness Index case Year 1 Michaelmas Term.
SHANNON KEHR PHYSIOLOGY APRIL 1, 2014 Muscle Relaxers.
2© Paradigm Publishing, Inc. Chapter 10 The Muscular System and Drug Therapy.
INDIRECT CHOLINOMIMETICS
The Neuromuscular Junction
Skeletal muscle relaxants
Pharmacology-1 PHL 313 Parasympathetic Nervous System Sixth Lecture By Abdelkader Ashour, Ph.D. Phone:
Motor System. Why is the Motor System Important? All observable behavior is directly related to activity in the motor system. Without the motor system,
Pharmacology DOR 101 Abdelkader Ashour, Ph.D. 5 th Lecture.
Skeletal muscle relaxants
NEUROMUSCULAR JUNCTION BLOCKERS BY :DR ISRAA OMAR.
MCMP 407 Spasmolytics Chronic neurologic diseases Cerebral Palsy, Multiple Sclerosis Acute Injury Spinal cord damage, muscle inflamation Goal of therapy:
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 25 Drugs for Muscle Spasm and Spasticity.
Skeletal Muscle Relaxants
Cholinergics, anticholinergics and antcholinesterases Nervous System Peripheral NS Sensory nerves Motor nerves Central NS (Brain and Spinal cord) Sensory.
GENERAL THORACIC SURGERY CHAPTER 168
Cholinergic agonists By Dr.Sajid Hussain
Myasthenia Gravis.  Describe myasthenia gravis  Signs and Symptoms of the disease  Describe the treatments available Purpose and Objectives.
How will you grade the spasticity of the patient?.
MYASTHENIA GRAVIS (MG)
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
MYASTHENIA GRAVIS ANESTHESIOLOGY Jasdeep Dhaliwal Clinical Rotation.
Spasticity Slide Library Version All Contents Copyright © WE MOVE 2001 Spasticity Pharmacological Treatment Part 4 of 6.
Pharmacology-1 PHL 351, Parasympathetic Nervous System Abdelkader Ashour, Ph.D. 6 th Lecture.
BIOS E-162B Undergraduate Review: Neuropathophysiology II and III October 4, 2010.
Slide 1 Copyright © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 13 Drugs Affecting the Autonomic Nervous System.
NEUROMUSCULAR JUNCTION BLOCKERS
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 19 Cholinergic Drugs.
Agents Used to Treat Seizures and Epilepsy Chapter 31.
Cholinergic drugs.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 20 Cholinergic Drugs.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 13 Drugs Affecting.
Pharmacology-1 PHL 211 Twelfth Lecture By Abdelkader Ashour, Ph.D. Phone:
Antispastics & Spasmolytic drugs that act centrally
Douglas Todey. Functions The three main functions of the muscle system are to produce motion, provide stability, and generate heat The three different.
ANTICHOLINESTERASES Acetylcholinesterase is an enzyme that specifically cleaves acetylcholine to acetate and choline. It is located both pre-and post-synaptically.
Drugs Affecting the Autonomic Nervous System
PYRAMID POINTS CHAPTER 68: MUSCULOSKELETAL MEDICATIONS.
Myasthenia Gravis.
Neurology Chapter of IAP
0No increase in muscle tone 1Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end range of motion when.
Autonomic Nervous System 6-Anticholinergic Drugs
MYASTHENIA GRAVIS “FROM WEAKNESS SHALL COME STRENGTH”. BY PATTI HAMILTON.
Chapter 45 Drugs Used to Treat the Muscular System 45-1 Mosby items and derived items © 2013, 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier.
SEDATIVE HYPNOTIC. USES  Short-term use (days to a few weeks) for insomnia; not for long term use  Long-term use (months or years); long-term use can.
Chapter 24 Drugs for Neuromuscular Disorders: Myasthenia Gravis, Multiple Sclerosis, and Muscle Spasms Copyright © 2015, 2012, 2009, 2006, 2003, 2000,
Autonomic Nervous System (ANS) Cholinergic Drugs 4 أ0م0د.وحدة بشير اليوزبكي.
Nursing management of Myasthenia Gravis
Chapter 13 Drugs Affecting Muscle Function Copyright © 2011 Delmar, Cengage Learning.
INDIRECT CHOLINOMIMETICS Prof. Hanan Hagar Pharmacology Department.
Myasthenia Gravis.
Understanding Medical Surgical Nursing, 4th Edition CHAPTER 50 Nursing Care of Patients with Peripheral Nervous System Disorders.
Jennifer Vilarino Period: 5
Neuromuscular disorders
Muscular Disorders and Diseases
Skeletal muscle relaxants
Drugs for Degenerative Diseases and Muscles
Spasticity ; Muscle Hypertonicity
Myasthenia Gravis Johan Perrand Period 3.
Spasticity Treatment Options
Cholinesterase Inhibitors (Indirect acting cholinergic agonists)
INDIRECT CHOLINOMIMETICS
Skeletal muscle relaxants
Skeletal muscle relaxants
Introduction to Clinical Pharmacology Chapter 26 Cholinergic Drugs
Presentation transcript:

Agents Used to Treat Musculoskeletal Health Alterations

Skeletal Muscle Also called striated muscle; is attached to the skeleton Contraction is under voluntary control Contraction controlled by the nervous system 2

Agents: Musculoskeletal Disorders Nerve impulses travel down the motor neurons of the nervous system Cause skeletal muscle contraction The neuromuscular junction contains the terminal of a motor neuron and a muscle fiber Motor axon terminals contain thousands of vesicles filled with acetylcholine 3

Classes:Musculoskeletal Drugs Neuromuscular blocking agents Centrally acting skeletal muscle relaxants Direct-acting skeletal muscle relaxants Skeletal muscle stimulants 4

Neuromuscular Blocking Agents Action Block the action of acetylcholine Mimic acetylcholine action and prevent cholinesterase from working; the muscle becomes overtired and the client is unable to use the muscle 5

Neuromuscular Blocking Agents Relax or paralyze the skeletal muscles Used for: Surgery Electroconvulsive therapy Endotracheal intubation Tetanus treatment 6

Neuromuscular Blocking Agents Used to relax one or more muscles Neuromuscular blockade Paralyze skeletal muscle groups Does not affect cardiac muscle To assist intubation and mechanical ventilation Usually administered IV Close monitoring required Antidotes should be readily available 7

Neuromuscular Blocking Agents Not useful for spasticity or rigidity of muscles caused by neurological disease or trauma Many drug interactions 8

Centrally Acting Skeletal Muscle Relaxants Depress the CNS in the brainstem, basal ganglia, and neurons of the spinal cord Do not act on the neuromuscular junction Relieve pain associated with skeletal muscle spasms—cerebral palsy High risk: sedation 9

Centrally-acting musculoskeletal agents Baclofen – PO (Kemstro), intrathecal (Lioresal) Spasticity from multiple sclerosis or spinal injury Carisoprodol (Soma) – PO Metaxalone (Skelaxin) – PO Should be taken with food 10

Centrally-acting musculoskeletal agents (cont’d) Diazepam (Valium) – PO, IM, IV May cause dependence Cannot be mixed in syringe with other drugs Discontinue gradually to avoid withdrawal reactions 11

Centrally Acting Skeletal Muscle Relaxants Use cautiously with other CNS depressants Administered orally or parenterally Patients should be cautious when performing activities due to sedation May cause dependence 12

Direct-Acting Skeletal Muscle Relaxants Inhibit calcium release from the skeletal muscles Muscle is then less responsive to nerve impulses Dantrolene acts directly on skeletal muscle; relaxes spastic muscle Used in the treatment of multiple sclerosis, cerebral palsy, spinal cord injury, and stroke 13

Adverse Effects Diarrhea GI upset Photosensitivity Changes in sensory perception Insomnia Depression Hepatotoxicity Hepatitis 14

Myasthenia Gravis Affects 1 in 20,000 people Development of skeletal muscle weakness Symptoms include drooping eyelids, difficulty swallowing, and inability to perform simple tasks 15

Myasthenia Gravis May be caused by damage to acetylcholine receptors at the neuromuscular junction Autoimmune reaction Therapy is aimed at increasing the concentration of acetylcholine at the neuromuscular junction 16

Myasthenia Gravis Neostigmine (Prostigmin) Pyridostigmine bromide (Mestinon) – most popularly used for PO Longer duration, better tolerated PO than neostigmine Edrophonium (Tensilon, Reversol) – parenteral (IV) used for diagnosis or MG crisis 17

Skeletal-Muscle Stimulants Correct muscular weakness such as myasthenia gravis Inhibits the action of anticholinesterase; more acetylcholine is available to cause and maintain the muscle contraction 18

Skeletal-Muscle Stimulants Side effects/adverse effects Caused by unusual cholinergic activity Increased salivation Diarrhea Intestinal cramping Bradycardia Miosis 19

Myasthenia Gravis: Nursing Considerations - assess muscle functioning with vital signs - watch for symptoms of myasthenic crisis - take medication before eating or activity - plan activities after taking medications - patients need to carry identification of condition 20